Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)
Status:
Completed
Trial end date:
2011-07-11
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to investigate the Dose Limiting Toxicities (DLTs),
pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2206 administered orally to
participants with advanced solid tumors. The preliminary efficacy of MK-2206 will also be
investigated.